Rhythm Pharmaceuticals Inc Stock News

Rhythm Pharmaceuticals <> has recorded the biggest intraday gain since November 2020 after Ladenburg Thalmann upgraded the commercial-stage biopharmaceutical company to Buy…

Aridis Pharmaceuticals ARDS +12%. Rhythm Pharmaceuticals RYTM +12%. 10x Genomics (TXG) -16%. iSpecimen ISPC -10%.

Upgrades HSBC upgraded the previous rating for Equinor ASA (NYSE: EQNR ) from Hold to Buy. For the fourth quarter, Equinor had an EPS of $1.35, compared to year-ago quarter EPS of $0.17. The current stock performance of Equinor shows a 52-week-high of $32.16 and a 52-week-low of $17.78. Moreover, at the end of the last trading period, the closing price was at $29.45. Argus Research upgraded the previous rating for Canadian National Railway Co (NYSE: CNI ) from Hold to Buy. For the fourth quarter, Canadian National Railway had an EPS of $1.36, compared to year-ago quarter EPS of $1.10. The current stock performance of Canadian National Railway shows a 52-week-high of $136.22 and a 52-week-low of $100.66. Moreover, at the end of the last trading period, the closing price was at $126.93. According to TD Securities, the prior rating for Equinix Inc (NASDAQ: EQIX ) was changed from Hold to Buy. For the fourth quarter, Equinix had an EPS of $6.22, compared to year-ago quarter EPS of $5.76. At the moment, the stock has a 52-week-high of $885.26 and a 52-week-low of $586.73.

RYTM has a label expansion for its lead molecule. The molecule is approved in another indication for over a year.

Rhythm Pharmaceuticals <> announces the first patient has been dosed with setmelanotide, the companys melanocortin-4 receptor (MC4R) agonist, in Phase 2 DAYBREAK clinical trial

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) gapped up prior to trading on Monday . The stock had previously closed at $9.64, but opened at $10.16. Rhythm Pharmaceuticals shares last traded at $10.16, with a volume of 6 shares trading hands. A number of research analysts have commented on the stock. The Goldman Sachs Group upgraded shares of [] The post Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up to $9.64 appeared first on ETF Daily News .

Wall Street analysts expect Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) to announce earnings per share (EPS) of ($1.00) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Rhythm Pharmaceuticals earnings, with estimates ranging from ($1.08) to ($0.91). Rhythm Pharmaceuticals reported earnings per share of ($0.79) during the same quarter last year, []

Wells Fargo & Company initiated coverage on shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) in a report issued on Wednesday morning, Analyst Price Targets reports. The brokerage issued an overweight rating and a $30.00 target price on the stock. Other analysts have also issued research reports about the stock. Morgan Stanley lowered shares of Rhythm Pharmaceuticals from []

Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) have received a consensus recommendation of Hold from the eight ratings firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and three have issued a buy recommendation on the company. The average 12 [] The post Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Average Rating of Hold from Brokerages appeared first on ETF Daily News .

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) concluded the trading at $8.83 on Friday, December 03 with a fall of -4.02% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $9.20 and 5Y monthly beta was reading 1.43 with its price kept floating in the Rhythm Pharmaceuticals Inc. (RYTM) Forecast: Revisiting The Past To Gain Insights For The Future Read More »

Millennium Management LLC lowered its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) by 13.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 156,816 shares of the companys stock after selling 23,711 shares during the period. Millennium Management []

Credit Suisse AG trimmed its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) by 6.5% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 23,802 shares of the companys stock after selling 1,654 shares during the quarter. Credit Suisse AGs holdings in Rhythm Pharmaceuticals were worth $467,000 []

Charles Schwab Investment Management Inc. raised its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) by 6.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 267,631 shares of the companys stock after acquiring an additional 15,409 shares during the quarter. Charles Schwab Investment Management []

Charles Schwab Investment Management Inc. increased its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) by 6.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 267,631 shares of the companys stock after buying an additional 15,409 shares during the period. Charles Schwab Investment Management Inc.s holdings in []